Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18069863 | 0.86 | CYP2A6 (0.47) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2949120 | 0.86 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL5476556 | 0.83 | CYP2A6 (0.65) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL5543498 | 0.83 | CYP2A6 (0.65) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL4324624 | 0.83 | CYP2A6 (0.75) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL27615372 | 0.83 | CYP2A6 (0.65) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL9883963 | 0.83 | CYP2A6 (0.65) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL4418009 | 0.80 | CYP2A6 (0.71) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL8435709 | 0.80 | CYP2A6 (0.61) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL5542371 | 0.80 | CYP2A6 (0.61) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7235569-B2 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH (US) | 2007-06-26 | — | — | US | disclosed |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | TPH1, TPH2, HTR3A | CYP2A6 1478/4885KEAP1 2597/4885NFE2L2 2528/4885 |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | TPH1, TPH2, HTR4 | CYP2A6 1274/4885KEAP1 2566/4885NFE2L2 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.